Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A randomised, double-blind, placebo-controlled trial with an open-label extension to assess the p... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection ... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'Complementary Herbal Approach to Rheumatoid Management Study (CHARMS)'. The following are the oth... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Open-Label, Single Dose Study to Investigate the Relative Bioavailability, Safety, and... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'Phase II Open-label Study Evaluating Ivonescimab in PD-1 Resistant Recurrent or Metastatic Nasoph... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137... Read More
Singapore, April 14 -- The Health Sciences Authority received information related to the study titled 'Evaluating the Clinical and Economic Outcomes of Adding Semaglutide to Standard of Care in Adult ... Read More